TNP-351 is an antifolate and dihydrofolate reductase (DHFR) inhibitor with potent antitumor activity against leukemia and solid tumor cells both in vitro and in vivo; it inhibits the proliferation of mouse L1210 leukemia cells and human CCRF-CEM lymphoblastic leukemia cells with ED50 values of 0.79 nM and 2.7 nM, respectively.